Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 08:50:00 19/09/2024 pm IST 5-day change 1st Jan Change
898.20 DKK +1.81% Intraday chart for Novo Nordisk A/S +0.86% +28.66%
LockThis article is reserved for members
To unlock the article, REGISTER!
Vous êtes déja client ? Log In
EU regulator backs use of Novo's Wegovy for obesity-related heart condition RE
Hims & Hers offers compounded Wegovy for $99 a month to select professions RE
NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases CI
Glum trade for FTSE 100 before Fed decides AN
Aragen Life Sciences Reportedly Plans to Dilute About 10% Stake CI
Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports RE
Health Care Down as Novo Nordisk Slides on Drug-Price Fears - Health Care Roundup DJ
Sector Update: Health Care Stocks Retreat Late Afternoon MT
Sector Update: Health Care MT
Novo Nordisk's Ozempic Likely to Face U.S. Price Negotiations, Bloomberg Reports DJ
US Senator Sanders says generic drugmakers could sell Ozempic for less than $100/month RE
Novo Nordisk Exec Says Ozempic 'Very Likely' to Face Drug Price Negotiations MT
Novo Nordisk Exec Says Ozempic 'Very Likely' to Face Drug Price Negotiations, Bloomberg Reports MT
Korro Bio Partners With Novo Nordisk to Develop Genetic Medicines MT
Korro Bio, Inc Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates CI
Eli Lilly invests $1.8 billion in Ireland sites to scale up Alzheimer's, obesity drug production RE
NOVO NORDISK : Deutsche Bank keeps its Buy rating ZD
Roche shares drop on side effects result in early-stage obesity pill trial RE
Health Care Down on Cyclical Bias -- Health Care Roundup DJ
Sector Update: Health Care Stocks Narrowly Mixed Premarket Wednesday MT
Novo Nordisk's Experimental Obesity Pill Could Be More Effective With Extended Use DJ
NOVO NORDISK : JP Morgan reiterates its Buy rating ZD
NOVO NORDISK : Gets a Neutral rating from UBS ZD
Novo Nordisk Reports Positive Results of Phase 3a Trial of Anti-Obesity Drug Liraglutide in Children MT
Health Care Up on Defensive Bias -- Health Care Roundup DJ
Chart Novo Nordisk A/S
More charts
Logo Novo Nordisk A/S
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Employees
69,260
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
898.20DKK
Average target price
967.54DKK
Spread / Average Target
+7.72%
Consensus
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. News Novo Nordisk A/S
  5. Top Midday Stories: Novo Nordisk Stock Slides After Q2 Miss, Lower Guidance; Disney EPS, Revenue Top Estimates; Apple's Union Workers Ratify Contract; Disney Likely to Pay More for Hulu